SELLAS Life Sciences recorded a $10.1 million loss in the third quarter as investors awaited results from the Phase 3 REGAL trial of galinpepimut S, an immunotherapy for acute myeloid leukemia. On October 28, the company said the study had reached its prespecified 80th event, triggering the final analysis of its primary overall survival endpoint. Following database lock, unblinding and statistical analysis, preliminary results are expected in the fourth quarter of 2026. SELLAS is also developing SLS009, a CDK9 inhibitor being evaluated in combination with existing treatments for acute myeloid leukemia. The company reported $138.3 million in cash and cash equivalents as of June 30.
Source: Read the original article


